News

Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials
Biogen (BIIB) announced new data that it says reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy. These latest findings from Part C ...
The Manila Times6d
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...
Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy
Biogen said that new data examining of its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates ...
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced ...
Nasdaq6d
Biogen Inc. Reports Positive Findings from DEVOTE and NURTURE Studies on Higher Dose Regimen of Nusinersen for Spinal Muscular Atrophy - Nasdaq
New data from Biogen shows improved motor function in SMA patients using a higher dose of nusinersen, highlighting early treatment benefits. Biogen announced new data from the DEVOTE Part C and ...
pharmaphorum7d
Biogen races into phase 3 with Spinraza follow-up
Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) ...
Clinical Trials Arena on MSN8d
Biogen’s Spinraza successor advances to Phase III
Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...
The Pharma Letter6d
New data for nusinersen underscore Biogen’s commitment to SMA
US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...
Morningstar6d
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA - Morningstar
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA Provided by GlobeNewswire Jun 27, 2025, 2:00:23 PM.
Financial Post6d
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA - Financial Post
CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected ...